Skip to main content
Medical information Clinical review pending

Cytogenetics

Fibroblast Growth Factor FGF2 Test

The Fibroblast Growth Factor FGF2 Test measures levels of FGF2, a protein linked to tumor growth and blood vessel formation. It aids in cancer diagnosis and monitoring.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
2 mL (minimum 1 mL) of plasma collected in a Lavender Top (EDTA) tube.
Results
Confirm with the laboratory before booking. Results are typically available within 2 to 3 weeks after sample receipt.
Preparation
Confirm with the laboratory before booking. No specific patient preparation is typically required, but follow any instructions provided by your doctor or the laboratory.
Test priceKSh 50,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Fibroblast Growth Factor FGF2 Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of certain cancers
  • ✓Monitoring cancer progression
  • ✓Assessing response to cancer treatment
  • ✓Evaluating tumor angiogenesis
  • ✓Patients with unexplained symptoms suggestive of cancer
02

In plain language

What this test helps you understand

This test helps oncologists assess tumor growth potential and angiogenesis. It can aid in diagnosing certain cancers, monitoring treatment effectiveness, and understanding prognosis.
The Fibroblast Growth Factor FGF2 Test is an advanced diagnostic tool used in the assessment and management of cancer. This test measures the concentration of Fibroblast Growth Factor 2 (FGF2) in the plasma. FGF2 is a protein that plays a significant role in angiogenesis, the process where new blood vessels are formed. Elevated levels of FGF2 can be associated with the presence and growth of tumors. Understanding FGF2 levels can provide valuable information to oncologists for diagnosis, treatment planning, and monitoring cancer progression. This test is particularly useful for individuals diagnosed with cancer or those at high risk.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationConfirm with the laboratory before booking. No specific patient preparation is typically required, but follow any instructions provided by your doctor or the laboratory.
Sample2 mL (minimum 1 mL) of plasma collected in a Lavender Top (EDTA) tube.
MethodologyConfirm with the laboratory before booking. The test typically involves measuring the concentration of FGF2 protein in the plasma sample.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test measures FGF2 levels in plasma. Results should be interpreted in conjunction with other clinical findings, imaging, and laboratory tests. Elevated FGF2 levels are not specific to cancer and can be seen in other conditions. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

FGF2 is a protein involved in cell growth, differentiation, and the formation of new blood vessels (angiogenesis). Elevated levels can be associated with certain cancers.
This test can help doctors diagnose cancer, monitor how well treatment is working, and understand the potential behavior of a tumor.
A blood sample is required. Specifically, plasma separated from a Lavender Top (EDTA) tube is needed.
Results are typically available within 2 to 3 weeks after the sample is collected and received by the laboratory. Confirm with the laboratory before booking.
While FGF2 levels can be elevated in various cancers, this test is not a universal cancer screening tool. Its utility depends on the specific type of cancer suspected. Confirm with the laboratory before booking.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp